A study of prospective surveillance for inhibitors among persons with haemophilia in the united states

Haemophilia

Volumn 20, Issue 2, 2014, Pages 230-237

  Soucie, J M ^a   Miller, C H ^a   Kelly, F M ^a   Payne, A B ^a   Creary, M ^a   Bockenstedt, P L ^b   Kempton, C L ^c   Manco Johnson, M J ^d   Neff, A T ^e   Abshire, Thomas C ^c   Brettler, Doreen B ^f   Di Paola, Jorge A ^g   Lentz, Steven R ^g   Radhi, Mohamed ^g   Massey, Gita ^h   Barrett, John C ^h   Shapiro, Amy D ⁱ   Tarantino, Michael ^j   Wicklund, Brian M ^k   Knoll, Christine ^l   Escobar, Miguel A ^m   Eyster, M Elaine ⁿ   Gill, Joan C ^o   Leissinger, Cindy ^p   Yaish, Hassan ^q   more..

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c EMORY UNIVERSITY   (United States)

^d Mountain States Regional Hemophilia and Thrombosis Center   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f New England Haemophilia Center   (United States)

^g UNIVERSITY OF IOWA   (United States)

^h VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

ⁱ INDIANA HEMOPHILIA AND THROMBOSIS CENTER   (United States)

^j Comprehensive Bleeding Disorders Center ^*  (United States)

^k Kansas City Cancer Center   (United States)

^l PHOENIX CHILDREN'S HOSPITAL   (United States)

^m Gulf States Hemophilia and Thrombophilia Center   (United States)

ⁿ Hemophilia Center of Central Pennsylvania   (United States)

^o Comprehensive Center for Bleeding Disorders ^*  (United States)

^p The Louisiana Center for Bleeding and Clotting Disorders   (United States)

^q PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

more..

Author keywords

Haemophilia; Haemophilia inhibitor; Surveillance

Indexed keywords

HAEMOPHILIA; HAEMOPHILIA INHIBITOR; SURVEILLANCE;

ADOLESCENT; ADULT; AGED; ANTIBODIES; CHILD; CHILD, PRESCHOOL; FACTOR IX; FACTOR VIII; FEMALE; HEMOPHILIA A; HEMOPHILIA B; HUMANS; INFANT; MALE; MIDDLE AGED; MUTATION; PROSPECTIVE STUDIES; PUBLIC HEALTH SURVEILLANCE; UNITED STATES; YOUNG ADULT;

EID: 84894261803     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12302     Document Type: Article

References (18)

1. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
2. Soucie JM, Symons J, Evatt B et al. Home-based factor infusion therapy and hospitalization for bleeding complications among males with haemophilia. Haemophilia 2001; 7: 198-206.
3. Ullman M, Hoots WK. Assessing the costs for clinical care of patients with high-responding factor VIII and IX inhibitors. Haemophilia 2006; 12(Suppl. 6): 74-80.
4. Guh S, Grosse SD, McAlister S, Kessler CM, Soucie JM. Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008. Haemophilia 2012; 18: 268-75.
5. Guh S, Grosse SD, McAlister S, Kessler CM, Soucie JM. Health care expenditures for Medicaid-covered males with haemophilia in the United States, 2008. Haemophilia 2012; 18: 276-83.
6. Food and Drug Administration. Workshop on factor VIII inhibitors. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/TranscriptsMinutes/UCM054451.pdf. Accessed December 2, 2011.
7. European Medicines Agency. Report of expert meeting on factor VIII products and inhibitor development 28 February 2006-2 March 2006. Available at: http://www.emea.europa.eu/docs/en_GB/document_library/Report/2009/11/WC500015512.pdf. Accessed December 2, 2011.
8. Soucie JM, McAlister S, McClellan A, Oakley M, Su Y. The universal data collection surveillance system for rare bleeding disorders. Am J Prev Med 2010; 4(Suppl.): S475-81.
9. Kempton CL, Soucie JM, Abshire TC. Incidence of inhibitors in a cohort of 838 males with haemophilia A previously treated with factor VIII concentrates. J Thromb Haemost 2006; 4: 2576-81.
10. Miller CH, Platt SJ, Rice AS, Kelly F, Soucie JM; Haemophilia Inhibitor Research Study Investigators. Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance. J Thromb Haemost 2012; 10: 1055-61.
11. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:c inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
12. Bagnall RD, Giannelli F, Green PM. Int22 h-related inversions causing haemophilia A: a novel insight into their origin and a new more discriminant PCR test for their detection. J Thromb Haemost 2006; 4: 591-8.
13. Bagnall RD, Waseem N, Green PM, Gianelli F. Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe haemophilia A. Blood 2002; 99: 168-74.
14. Goldman SA. Limitations and strengths of spontaneous reports data. Clin Therap 1998; 20(Suppl. C): C40-4.
15. Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 1999; 281: 824-9.
16. Peerlinck K, Arnout J, Di Giambattista M et al. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb Haemost 1997; 77: 80-6.
17. Hay CR, DiMichele DM; International Immune Tolerance Study. The principle results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 19: 1335-44.
18. CDC Haemophilia A Mutation Project (CHAMP) Mutation List. http://www.cdc.gov/haemophiliamutations. Accessed January 6, 2012.